Discover six bispecific antibody companies developing a two-in-one approach to delivering targeted therapeutics to patients.

Zanidatamab is the first agent approved specifically for advanced, HER2-positive second-line biliary tract cancer.

Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, ...

Dr Laura Moriarty, senior marketing manager at Bio-Rad, looks at the impressive immuno-therapeutic potential of bispecific antibodies (bsAbs). Bispecific antibodies (bsAbs) are designed to ...

A team from Nanjing Leads Biolabs Co. Ltd. presented the discovery and preclinical characterization of LBL-042, a novel bispecific antibody designed to simultaneously target PD-1 and LILRB1/2, with ...

Bispecific ADCs represent a cutting-edge advancement, leveraging bispecific antibodies that can target two distinct antigens or epitopes, enhancing the therapeutic index of ADCs by increasing ...

BioNTech (NASDAQ:BNTX) said it has agreed to buy bispecific antibody developer Biotheus for up to $950M, including $150M in potential milestone payments. Under the deal, BioNTech (BNTX) will pay $800M ...

ImmunoPrecise Antibodies, an AI-driven biotherapeutic research and technology company, has entered into a material transfer ...

VEGF bispecifics. | Merck and BioNTech are buying Chinese biotechs to gain PD-(L)1/VEGF bispecifics. AstraZeneca's CEO argued ...

The Orphan Drug designation was supported by preclinical research and preliminary data from the dose escalation/expansion phase 1/2 trial.